Neuropeptides
Volume 44, Issue 2 , Pages 119-125 , April 2010

Kinins in cardiac inflammation and regeneration: Insights from ischemic and diabetic cardiomyopathy

  • Konstantinos Savvatis

      Affiliations

    • Charité – Universitätsmedizin Berlin, Department of Cardiology and Pneumonology, Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany
    • ,
  • Dirk Westermann

      Affiliations

    • Charité – Universitätsmedizin Berlin, Department of Cardiology and Pneumonology, Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany
    • ,
  • Heinz-Peter Schultheiss

      Affiliations

    • Charité – Universitätsmedizin Berlin, Department of Cardiology and Pneumonology, Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany
    • ,
  • Carsten Tschöpe

      Affiliations

    • Charité – Universitätsmedizin Berlin, Department of Cardiology and Pneumonology, Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany
    • Charité – Universitätsmedizin Berlin, Berlin–Brandenburg Center for Regenerative Therapies, Campus Virchow-Klinikum, Augustenburger Platz 1, 13353 Berlin, Germany
    • Corresponding Author InformationCorresponding author. Address: Department of Cardiology, Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany. Tel.: +49 (0) 30 8445 2349; fax: +49 (0) 30 8445 4648.

References 

  1. Alfie ME, Yang XP, Hess F, Carretero OA. Salt-sensitive hypertension in bradykinin B2 receptor knockout mice. Biochem. Biophys. Res. Commun. 1996;224:625–630
  2. Alfie ME, Sigmon DH, Pomposiello SI, Carretero OA. Effect of high salt intake in mutant mice lacking bradykinin-B2 receptors. Hypertension. 1997;29:483–487
  3. Barcelos LS, Duplaa C, Krankel N, Graiani G, Invernici G, Katare R, et al. Human CD133+ progenitor cells promote the healing of diabetic ischemic ulcers by paracrine stimulation of angiogenesis and activation of Wnt signaling. Circ. Res. 2009;104:1095–1102
  4. Bertram CM, Baltic S, Misso NL, Bhoola KD, Foster PS, Thompson PJ, et al. Expression of kinin B1 and B2 receptors in immature, monocyte-derived dendritic cells and bradykinin-mediated increase in intracellular Ca2+ and cell migration. J. Leukoc. Biol. 2007;81:1445–1454
  5. Blais C, Drapeau G, Raymond P, Lamontagne D, Gervais N, Venneman I, et al. Contribution of angiotensin-converting enzyme to the cardiac metabolism of bradykinin: an interspecies study. Am. J. Physiol. 1997;273:H2263–H2271
  6. Calixto JB, Medeiros R, Fernandes ES, Ferreira J, Cabrini DA, Campos MM. Kinin B1 receptors: key G-protein-coupled receptors and their role in inflammatory and painful processes. Br. J. Pharmacol. 2004;143:803–818
  7. Campos MM, Souza GE, Calixto JB. In vivo B1 kinin-receptor upregulation. Evidence for involvement of protein kinases and nuclear factor kappaB pathways. Br. J. Pharmacol. 1999;127:1851–1859
  8. Cayla C, Todiras M, Iliescu R, Saul VV, Gross V, Pilz B, et al. Mice deficient for both kinin receptors are normotensive and protected from endotoxin-induced hypotension. FASEB J. 2007;21:1689–1698
  9. Chao J, Yin H, Gao L, Hagiwara M, Shen B, Yang ZR, et al. Tissue kallikrein elicits cardio protection by direct kinin b2 receptor activation independent of kinin formation. Hypertension. 2008;52:715–720
  10. Chavakis T, Kanse SM, Pixley RA, May AE, Isordia-Salas I, Colman RW, et al. Regulation of leukocyte recruitment by polypeptides derived from high molecular weight kininogen. FASEB J. 2001;15:2365–2376
  11. Chen S, Khan ZA, Cukiernik M, Chakrabarti S. Differential activation of NF-kappa B and AP-1 in increased fibronectin synthesis in target organs of diabetic complications. Am. J. Physiol. Endocrinol. Metab. 2003;284:E1089–E1097
  12. Christopher J, Velarde V, Zhang D, Mayfield D, Mayfield RK, Jaffa AA. Regulation of B(2)-kinin receptors by glucose in vascular smooth muscle cells. Am. J. Physiol. Heart Circ. Physiol. 2001;280:H1537–H1546
  13. Dabek J, Kulach A, Smolka G, Wilczok T, Scieszka J, Gasior Z. Expression of genes encoding kinin receptors in peripheral blood mononuclear cells from patients with acute coronary syndromes. Intern. Med. J. 2008;38:892–896
  14. Decarie A, Raymond P, Gervais N, Couture R, Adam A. Serum interspecies differences in metabolic pathways of bradykinin and [des-Arg9]BK: influence of enalaprilat. Am. J. Physiol. 1996;271:H1340–H1347
  15. Dos Santos AC, Roffe E, Arantes RM, Juliano L, Pesquero JL, Pesquero JB, et al. Kinin B2 receptor regulates chemokines CCL2 and CCL5 expression and modulates leukocyte recruitment and pathology in experimental autoimmune encephalomyelitis (EAE) in mice. J. Neuroinflamm. 2008;5:49
  16. Duchene J, Lecomte F, Ahmed S, Cayla C, Pesquero J, Bader M, et al. A novel inflammatory pathway involved in leukocyte recruitment: role for the kinin B1 receptor and the chemokine CXCL5. J. Immunol. 2007;179:4849–4856
  17. Duka I, Kintsurashvili E, Gavras I, Johns C, Bresnahan M, Gavras H. Vasoactive potential of the b(1) bradykinin receptor in normotension and hypertension. Circ. Res. 2001;88:275–281
  18. Duka A, Kintsurashvili E, Duka I, Ona D, Hopkins TA, Bader M, et al. Angiotensin-converting enzyme inhibition after experimental myocardial infarct: role of the kinin B1 and B2 receptors. Hypertension. 2008;51:1352–1357
  19. Emanueli C, Zacheo A, Minasi A, Chao J, Chao L, Salis MB, et al. Adenovirus-mediated human tissue kallikrein gene delivery induces angiogenesis in normoperfused skeletal muscle. Arterioscler. Thromb. Vasc. Biol. 2000;20:2379–2385
  20. Emanueli C, Minasi A, Zacheo A, Chao J, Chao L, Salis MB, et al. Local delivery of human tissue kallikrein gene accelerates spontaneous angiogenesis in mouse model of hindlimb ischemia. Circulation. 2001;103:125–132
  21. Emanueli C, Salis MB, Van Linthout S, Meloni M, Desortes E, Silvestre JS, et al. Akt/protein kinase B and endothelial nitric oxide synthase mediate muscular neovascularization induced by tissue kallikrein gene transfer. Circulation. 2004;110:1638–1644
  22. Erdös EG. Bradykinin, kallidin and kallikrein. In:  Erdös EG editors. Handbook of Experimental Pharmacology. vol. 25:Berlin: Springer; 1970;p. 427–487
  23. Erdös EG. The kinins. A status report. Biochem. Pharmacol. 1976;25:1563–1569
  24. Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc. Res. 2002;53:31–47
  25. Ganju P, Davis A, Patel S, Nunez X, Fox A. P38 stress-activated protein kinase inhibitor reverses bradykinin B(1) receptor-mediated component of inflammatory hyperalgesia. Eur. J. Pharmacol. 2001;421:191–199
  26. Helske S, Laine M, Kupari M, Lommi J, Turto H, Nurmi L, et al. Increased expression of profibrotic neutral endopeptidase and bradykinin type 1 receptors in stenotic aortic valves. Eur. Heart J. 2007;28:1894–1903
  27. Hoang MV, Turner AJ. Novel activity of endothelin-converting enzyme: hydrolysis of bradykinin. Biochem. J. 1997;327(Pt 1):23–26
  28. Ignjatovic T, Tan F, Brovkovych V, Skidgel RA, Erdos EG. Novel mode of action of angiotensin I converting enzyme inhibitors: direct activation of bradykinin B1 receptor. J. Biol. Chem. 2002;277:16847–16852
  29. Kakoki M, Smithies O. The kallikrein–kinin system in health and in diseases of the kidney. Kidney Int. 2009;75:1019–1030
  30. Koch M, Wendorf M, Dendorfer A, Wolfrum S, Schulze K, Spillmann F, et al. Cardiac kinin level in experimental diabetes mellitus: role of kininases. Am. J. Physiol. Heart Circ. Physiol. 2003;285:H418–H423
  31. Koch M, Spillmann F, Dendorfer A, Westermann D, Altmann C, Sahabi M, et al. Cardiac function and remodeling is attenuated in transgenic rats expressing the human kallikrein-1 gene after myocardial infarction. Eur. J. Pharmacol. 2006;550:143–148
  32. Koch M, Bonaventura K, Spillmann F, Dendorfer A, Schultheiss HP, Tschope C. Attenuation of left ventricular dysfunction by an ACE inhibitor after myocardial infarction in a kininogen-deficient rat model. Biol. Chem. 2008;389:719–723
  33. Krankel N, Katare RG, Siragusa M, Barcelos LS, Campagnolo P, Mangialardi G, et al. Role of kinin B2 receptor signaling in the recruitment of circulating progenitor cells with neovascularization potential. Circ. Res. 2008;103:1335–1343
  34. Leeb-Lundberg LM, Marceau F, Muller-Esterl W, Pettibone DJ, Zuraw BL. International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol. Rev. 2005;57:27–77
  35. Liesmaa I, Kuoppala A, Shiota N, Kokkonen JO, Kostner K, Mayranpaa M, et al. Increased expression of bradykinin type-1 receptors in endothelium of intramyocardial coronary vessels in human failing hearts. Am. J. Physiol. Heart Circ. Physiol. 2005;288:H2317–H2322
  36. Liu YH, Yang XP, Mehta D, Bulagannawar M, Scicli GM, Carretero OA. Role of kinins in chronic heart failure and in the therapeutic effect of ACE inhibitors in kininogen-deficient rats. Am. J. Physiol. Heart Circ. Physiol. 2000;278:H507–H514
  37. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, et al. Heart disease and stroke statistics-2009 update: a report from the American heart association statistics committee and stroke statistics subcommittee. Circulation. 2009;119:480–486
  38. Lu G, Kang YJ, Han J, Herschman HR, Stefani E, Wang Y. TAB-1 modulates intracellular localization of p38 MAP kinase and downstream signaling. J. Biol. Chem. 2006;281:6087–6095
  39. Madeddu P, Varoni MV, Palomba D, Emanueli C, Demontis MP, Glorioso N, et al. Cardiovascular phenotype of a mouse strain with disruption of bradykinin B2-receptor gene. Circulation. 1997;96:3570–3578
  40. Marceau F, Gendreau M, Barabe J, St-Pierre S, Regoli D. The degradation of bradykinin (BK) and of des-Arg9-BK in plasma. Can. J. Physiol. Pharmacol. 1981;59:131–138
  41. Marceau F, Hess JF, Bachvarov DR. The B1 receptors for kinins. Pharmacol. Rev. 1998;50:357–386
  42. Montanari D, Yin H, Dobrzynski E, Agata J, Yoshida H, Chao J, et al. Kallikrein gene delivery improves serum glucose and lipid profiles and cardiac function in streptozotocin-induced diabetic rats. Diabetes. 2005;54:1573–1580
  43. Moreno PR, Sanz J, Fuster V. Promoting mechanisms of vascular health: circulating progenitor cells, angiogenesis, and reverse cholesterol transport. J. Am. Coll. Cardiol. 2009;53:2315–2323
  44. Mudd JO, Kass DA. Tackling heart failure in the twenty-first century. Nature. 2008;451:919–928
  45. Ni A, Yin H, Agata J, Yang Z, Chao L, Chao J. Overexpression of kinin B1 receptors induces hypertensive response to des-Arg9-bradykinin and susceptibility to inflammation. J. Biol. Chem. 2003;278:219–225
  46. Olsson M, Dalsgaard CJ, Haegerstrand A, Rosenqvist M, Ryden L, Nilsson J. Accumulation of T lymphocytes and expression of interleukin-2 receptors in nonrheumatic stenotic aortic valves. J. Am. Coll. Cardiol. 1994;23:1162–1170
  47. Parenti A, Morbidelli L, Ledda F, Granger HJ, Ziche M. The bradykinin/B1 receptor promotes angiogenesis by up-regulation of endogenous FGF-2 in endothelium via the nitric oxide synthase pathway. FASEB J. 2001;15:1487–1489
  48. Passos GF, Fernandes ES, Campos MM, Araujo JG, Pesquero JL, Souza GE, et al. Kinin B1 receptor up-regulation after lipopolysaccharide administration: role of proinflammatory cytokines and neutrophil influx. J. Immunol. 2004;172:1839–1847
  49. Pesquero JB, Araujo RC, Heppenstall PA, Stucky CL, Silva JA, Walther T, et al. Hypoalgesia and altered inflammatory responses in mice lacking kinin B1 receptors. Proc. Natl. Acad. Sci. USA. 2000;97:8140–8145
  50. Proud D, Baumgarten CR, Naclerio RM, Ward PE. Kinin metabolism in human nasal secretions during experimentally induced allergic rhinitis. J. Immunol. 1987;138:428–434
  51. Regoli D, Barabe J. Pharmacology of bradykinin and related kinins. Pharmacol. Rev. 1980;32:1–46
  52. Regoli DC, Marceau F, Lavigne J. Induction of beta 1-receptors for kinins in the rabbit by a bacterial lipopolysaccharide. Eur. J. Pharmacol. 1981;71:105–115
  53. Riad A, Zhuo JL, Schultheiss HP, Tschope C. The role of the renal kallikrein–kinin system in diabetic nephropathy. Curr. Opin. Nephrol. Hypertens. 2007;16:22–26
  54. Riad A, Walther T, Yang J, Altmann C, Escher F, Westermann D, et al. The cardiovascular influence of interleukin-1 beta on the expression of bradykinin B1 and B2 receptors. Int. Immunopharmacol. 2008;8:222–230
  55. Riad A, Bien S, Westermann D, Becher PM, Loya K, Landmesser U, et al. Pretreatment with statin attenuates the cardio toxicity of doxorubicin in mice. Cancer Res. 2009;69:695–699
  56. Schanstra JP, Neau E, Drogoz P, Arevalo Gomez MA, Lopez Novoa JM, Calise D, et al. In vivo bradykinin B2 receptor activation reduces renal fibrosis. J. Clin. Invest. 2002;110:371–379
  57. Schulze-Topphoff U, Prat A, Bader M, Zipp F, Aktas O. Roles of the kallikrein/kinin system in the adaptive immune system. Int. Immunopharmacol. 2008;8:155–160
  58. Schulze-Topphoff U, Prat A, Prozorovski T, Siffrin V, Paterka M, Herz J, et al. Activation of kinin receptor B1 limits encephalitogenic T lymphocyte recruitment to the central nervous system. Nat. Med. 2009;15:788–793
  59. Skidgel RA, Engelbrecht S, Johnson AR, Erdos EG. Hydrolysis of substance p and neurotensin by converting enzyme and neutral endopeptidase. Peptides. 1984;5:769–776
  60. Spillmann F, Altmann C, Scheeler M, Barbosa M, Westermann D, Schultheiss HP, et al. Regulation of cardiac bradykinin B1- and B2-receptor mRNA in experimental ischemic, diabetic, and pressure-overload-induced cardiomyopathy. Int. Immunopharmacol. 2002;2:1823–1832
  61. Spillmann F, Graiani G, Van Linthout S, Meloni M, Campesi I, Lagrasta C, et al. Regional and global protective effects of tissue kallikrein gene delivery to the peri-infarct myocardium. Regen. Med. 2006;1:235–254
  62. Stone OA, Richer C, Emanueli C, van Weel V, Quax PH, Katare R, et al. Critical role of tissue kallikrein in vessel formation and maturation: implications for therapeutic revascularization. Arterioscler. Thromb. Vasc. Biol. 2009;29:657–664
  63. Trabold F, Pons S, Hagege AA, Bloch-Faure M, Alhenc-Gelas F, Giudicelli JF, et al. Cardiovascular phenotypes of kinin B2 receptor- and tissue kallikrein-deficient mice. Hypertension. 2002;40:90–95
  64. Tschope C, Westermann D. Development of diabetic cardiomyopathy and the kallikrein–kinin system–new insights from B1 and B2 receptor signaling. Biol. Chem. 2008;389:707–711
  65. Tschope C, Reinecke A, Seidl U, Yu M, Gavriluk V, Riester U, et al. Functional, biochemical, and molecular investigations of renal kallikrein–kinin system in diabetic rats. Am. J. Physiol. 1999;277:H2333–H2340
  66. Tschope C, Walther T, Yu M, Reinecke A, Koch M, Seligmann C, et al. Myocardial expression of rat bradykinin receptors and two tissue kallikrein genes in experimental diabetes. Immunopharmacology. 1999;44:35–42
  67. Tschope C, Heringer-Walther S, Walther T. Regulation of the kinin receptors after induction of myocardial infarction: a mini-review. Braz. J. Med. Biol. Res. 2000;33:701–708
  68. Tschope C, Schultheiss HP, Walther T. Multiple interactions between the renin-angiotensin and the kallikrein–kinin systems: role of ACE inhibition and AT1 receptor blockade. J. Cardiovasc. Pharmacol. 2002;39:478–487
  69. Tschope C, Spillmann F, Altmann C, Koch M, Westermann D, Dhayat N, et al. The bradykinin B1 receptor contributes to the cardioprotective effects of AT1 blockade after experimental myocardial infarction. Cardiovasc. Res. 2004;61:559–569
  70. Tschope C, Spillmann F, Rehfeld U, Koch M, Westermann D, Altmann C, et al. Improvement of defective sarcoplasmic reticulum Ca2+ transport in diabetic heart of transgenic rats expressing the human kallikrein-1 gene. FASEB J. 2004;18:1967–1969
  71. Tschope C, Walther T, Koniger J, Spillmann F, Westermann D, Escher F, et al. Prevention of cardiac fibrosis and left ventricular dysfunction in diabetic cardiomyopathy in rats by transgenic expression of the human tissue kallikrein gene. FASEB J. 2004;18:828–835
  72. Tschope C, Walther T, Escher F, Spillmann F, Du J, Altmann C, et al. Transgenic activation of the kallikrein–kinin system inhibits intramyocardial inflammation, endothelial dysfunction and oxidative stress in experimental diabetic cardiomyopathy. FASEB J. 2005;19:2057–2059
  73. Van Linthout S, Seeland U, Riad A, Eckhardt O, Hohl M, Dhayat N, et al. Reduced MMP-2 activity contributes to cardiac fibrosis in experimental diabetic cardiomyopathy. Basic. Res. Cardiol. 2008;103:319–327
  74. Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ. Res. 2001;89:E1–E7
  75. Wang DZ, Chao L, Chao J. Hypotension in transgenic mice overexpressing human bradykinin B2 receptor. Hypertension. 1997;29:488–493
  76. Westermann D, Rutschow S, Van Linthout S, Linderer A, Bucker-Gartner C, Sobirey M, et al. Inhibition of p38 mitogen-activated protein kinase attenuates left ventricular dysfunction by mediating pro-inflammatory cardiac cytokine levels in a mouse model of diabetes mellitus. Diabetologia. 2006;49:2507–2513
  77. Westermann D, Van Linthout S, Dhayat S, Dhayat N, Schmidt A, Noutsias M, et al. Tumor necrosis factor-alpha antagonism protects from myocardial inflammation and fibrosis in experimental diabetic cardiomyopathy. Basic Res. Cardiol. 2007;102:500–507
  78. Westermann D, Lettau O, Sobirey M, Riad A, Bader M, Schultheiss HP, et al. Doxorubicin cardiomyopathy-induced inflammation and apoptosis are attenuated by gene deletion of the kinin B1 receptor. Biol. Chem. 2008;389:713–718
  79. Westermann D, Walther T, Savvatis K, Escher F, Sobirey M, Riad A, et al. Gene deletion of the kinin receptor B1 attenuates cardiac inflammation and fibrosis during the development of experimental diabetic cardiomyopathy. Diabetes. 2009;58:1373–1381
  80. Wojakowski W, Kucia M, Kazmierski M, Ratajczak MZ, Tendera M. Circulating progenitor cells in stable coronary heart disease and acute coronary syndromes: relevant reparatory mechanism?. Heart. 2008;94:27–33
  81. Xu J, Carretero OA, Sun Y, Shesely EG, Rhaleb NE, Liu YH, et al. Role of the B1 kinin receptor in the regulation of cardiac function and remodeling after myocardial infarction. Hypertension. 2005;45:747–753
  82. Xu J, Carretero OA, Shesely EG, Rhaleb NE, Yang JJ, Bader M, et al. The kinin B1 receptor contributes to the cardioprotective effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in mice. Exp. Physiol. 2009;94:322–329
  83. Yin H, Chao J, Bader M, Chao L. Differential role of kinin B1 and B2 receptors in ischemia-induced apoptosis and ventricular remodeling. Peptides. 2007;28:1383–1389

PII: S0143-4179(09)00136-X

doi: 10.1016/j.npep.2009.11.007

Neuropeptides
Volume 44, Issue 2 , Pages 119-125 , April 2010

Article Tools

* Image Usage & Resolution